Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Only the Oncotype DX Breast Recurrence Score® Test Can Identify Patients Who May, or May Not, Benefit From Chemotherapy.1-5 EndoPredict® Cannot.

EndoPredict lacks clinical evidence showing that patients with EPclin* high-risk results may benefit from chemotherapy

Graph Breast Recurrence Score vs EndoPredict

 

EndoPredict may lead to unnecessary chemotherapy treatment based on its risk classification result

 

Graph EPclin Low Risk vs High Risk

 

EndoPredict has not been validated to show prediction of chemotherapy benefit

  • EndoPredict claims to be chemopredictive, but lacks randomized data within a homogenized cohort
  • EndoPredict does not stratify patients by nodal status, significantly skewing recurrence risks
  • Effect of chemotherapy does not vary between EPclinand EP molecular score results, suggesting that EndoPredict does not add any additional information beyond clinicopathologic features
  • Only the Oncotype DX Breast Recurrence Score test result has been proven to predict chemotherapy benefit in both node-negative and node-positive patients.2,4

    See why the Breast Recurrence Score test rises above

      

    *EPclin algorithm: nodal status + tumor size + EP (molecular score).
    HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NSABP B-20 = National Surgical Adjuvant Breast and Bowel Project; TAILORx = Trial Assigning Individualized Options for Treatment.

    Icon doctor

    Use our online physician portal

    Order tests, access results, receive updates, and more in one place.
    Sign up now